HomeTravelCarnival CEO: Expecting over 30% earnings growth in 2025

Carnival CEO: Expecting over 30% earnings growth in 2025

March 21, 2025

268

Josh Weinstein, Carnival Corp. CEO, joins ‘Money Movers’ to discuss the company’s quarterly earnings results, if the demand can remain strong, and much more.

04:08

5 hours ago

Source

Social Media Influencing The Strong Demand for Porcelain Veneers Procedure In Sydney

Heathrow shutdown is a ‘dramatic learning curve’ in airport crisis management, expert says

admin https://raveaboutit.com.au

Most Popular

Carnival CEO: Expecting over 30% earnings growth in 2025

FBI tracks down centuries-old Christian artifact in unexpected place: ‘Incredibly exciting’

AirAsia CEO on optimizing its fleet with record Airbus deal

Despite higher energy prices, there’s an opportunity in travel stocks, says Janus’ Jeremiah Buckley

Most Popular

Guangdong province: 139th Canton Fair sets new record with overseas buyer attendance

FBI tracks down centuries-old Christian artifact in unexpected place: ‘Incredibly exciting’

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

James Tedesco makes State of Origin statement as Roosters make it six straight

Recent Comments

EDITOR PICKS

Guangdong province: 139th Canton Fair sets new record with overseas buyer attendance

FBI tracks down centuries-old Christian artifact in unexpected place: ‘Incredibly exciting’

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

POPULAR POSTS

Guangdong province: 139th Canton Fair sets new record with overseas buyer attendance

FBI tracks down centuries-old Christian artifact in unexpected place: ‘Incredibly exciting’

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

POPULAR CATEGORY

ABOUT US

FOLLOW US